Use of multimodality imaging and artificial intelligence for diagnosis and prognosis of early stages of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
&NA; Alzheimer's disease (AD) is a major neurodegenerative disease and the most common cause of dementia. Currently, no treatment exists to slow down or stop the progression of AD. There is converging belief that disease‐modifying treatments should focus on early stages of the disease, that is, the mild cognitive impairment (MCI) and preclinical stages. Making a diagnosis of AD and offering a prognosis (likelihood of converting to AD) at these early stages are challenging tasks but possible with the help of multimodality imaging, such as magnetic resonance imaging (MRI), fluorodeoxyglucose (FDG)‐positron emission topography (PET), amyloid‐PET, and recently introduced tau‐PET, which provides different but complementary information. This article is a focused review of existing research in the recent decade that used statistical machine learning and artificial intelligence methods to perform quantitative analysis of multimodality image data for diagnosis and prognosis of AD at the MCI or preclinical stages. We review the existing work in 3 subareas: diagnosis, prognosis, and methods for handling modality‐wise missing data—a commonly encountered problem when using multimodality imaging for prediction or classification. Factors contributing to missing data include lack of imaging equipment, cost, difficulty of obtaining patient consent, and patient drop‐off (in longitudinal studies). Finally, we summarize our major findings and provide some recommendations for potential future research directions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 8×
“Over 5.4 million Americans presently suffer from AD.”
InfluentialSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2362 · Cited by 734 · cited 8×
“Over 5.4 million Americans presently suffer from AD.”
InfluentialJack, C. R., Knopman, D. S., Weigand, S. D., Wiste, H. J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22628 · Cited by 602
Young, J., Modat, M., Cardoso, M. J., Mendelson, A., Cash, D., & Ourselin, S. (2013) · NeuroImage Clinical · doi:10.1016/j.nicl.2013.05.004 · Cited by 249 · cited 4×
“Young et al.(22) MCI MRI, FDG-PET CSF and APOE Cross-sectional GP for AD vs NC, applied to MCI ADNI 47 MCI-c vs 96 MCI-nc 0.”
InfluentialBrain injury biomarkers are not dependent on β‐amyloid in normal elderly
Knopman, D. S., Jack, C. R., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23816 · Cited by 183
Wirth, M., Villeneuve, S., Haase, C. M., Madison, C. M., Oh, H., Landau, S. M., Rabinovici, G. D., & Jagust, W. J. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4013 · Cited by 171 · cited 1×
“Several studies also found that individuals with both markers of amyloid deposition and neurodegeneration were more likely to develop cognitive impairments at follow-up.(10,11) On the other hand, several studies found that there were cognitively normal, elderly individuals who had at least 1 significant neurodegenerat…”
Knopman, D. S., Jack, C. R., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.182 · Cited by 68 · cited 2×
“Several groups found hypometabolism in cognitively normal individuals with significant amyloid deposition.(7,8) In the study by Yi et al,(9) hypermetabolism was demonstrated in frontal and anterior temporal regions in cognitive normal apolipoprotein E (APOE) ε4 carriers but hypometabolism in temporoparietal regions.”
Cited by
CNN-based transfer learning–BiLSTM network: A novel approach for COVID-19 infection detection
Aslan, M. F., Unlersen, M. F., Sabanci, K., & Durdu, A. (2021) · Applied Soft Computing · doi:10.1016/j.asoc.2020.106912 · Cited by 354
Health benefits of dietary marine DHA/EPA-enriched glycerophospholipids
Zhang, T.-T., Xu, J., Wang, Y.-M., & Xue, C.-H. (2019) · Progress in Lipid Research · doi:10.1016/j.plipres.2019.100997 · Cited by 339
van Oostveen, W. M., & de Lange, E. C. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042110 · Cited by 297
“Nowadays, imaging modalities focus on either identifying amyloid deposition or identifying neurodegeneration [24].”
BackgroundInfluentialDeep neural networks in psychiatry
Durstewitz, D., Koppe, G., & Meyer-Lindenberg, A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0365-9 · Cited by 278
Explainable AI for Healthcare: From Black Box to Interpretable Models
Adadi, A., & Berrada, M. (2020) · Advances in Intelligent Systems and Computing · doi:10.1007/978-981-15-0947-6_31 · Cited by 137
Metadata
- Authors
- Liu, X., Chen, K., Wu, T., Weidman, D., Lure, F., & Li, J.
- Venue
- Translational Research
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 194
- Pages
- 56-67
- ISSN
- 1878-1810 (ISSN-L)
- 1931-5244
- OpenAlex
- W2782743885
- Cited by
- 141
- References
- 9
- FWCI
- 8.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of multimodality imaging and artificial intelligence for diagnosis and prognosis of early stages of Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.trsl.2018.01.001
- The paper
- Liu, X., Chen, K., Wu, T., Weidman, D., Lure, F., & Li, J. (2018). Use of multimodality imaging and artificial intelligence for diagnosis and prognosis of early stages of Alzheimer's disease. Translational Research. https://doi.org/10.1016/j.trsl.2018.01.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.